Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.31 |
| ▸ | PAFAH1B2 | P68402 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9702696 | 0.83 | LPAR3 (0.47) | LPAR3LPAR2TSHRALDH1A1LMNA | |
| SCHEMBL2962258 | 0.82 | FAAH (0.47) | LPAR3LPAR2FAAH | |
| SCHEMBL2954341 | 0.82 | LPAR3 (0.46) | LPAR3LPAR2TSHRALDH1A1LMNA | |
| SCHEMBL9701761 | 0.81 | LPAR3 (0.45) | LPAR3LPAR2TSHRALDH1A1LMNA | |
| SCHEMBL2960861 | 0.80 | PPARD (0.44) | TSHRALDH1A1LMNAFAAHMEN1 | |
| SCHEMBL2955740 | 0.79 | LPAR3 (0.47) | LPAR3LPAR2TSHRALDH1A1LMNA | |
| SCHEMBL8993904 | 0.79 | LPAR3 (0.47) | LPAR3LPAR2TSHRALDH1A1LMNA | |
| SCHEMBL9701750 | 0.79 | LPAR3 (0.47) | LPAR3LPAR2TSHRALDH1A1LMNA | |
| SCHEMBL24354774 | 0.78 | ALDH1A1 (0.46) | LPAR3LPAR2TSHRALDH1A1LMNA | |
| SCHEMBL1219734 | 0.77 | PPARD (0.47) | LPAR3LPAR2TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754200-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754200-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754200-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-20060280719-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2006-12-14 | — | — | US | disclosed |
| US-7109184-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1485391-B1 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORP (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1485391-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040019020-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003080630-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060280719-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC43A1 | LPAR3 1651/4885LPAR2 1433/4885TSHR 76/4885 |
| US-20040019020-A1 | Phosphate transport inhibitors | SLC34A2, SLC43A1, SLC34A1 | LPAR3 2860/4885LPAR2 2181/4885TSHR 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.